Risk of lymphoid malignancy associated with cancer predisposition genes - Top-Institutions - MDSpire

Risk of lymphoid malignancy associated with cancer predisposition genes

  • By

  • Nicholas J. Boddicker

  • Raphael Mwangi

  • Dennis P. Robinson

  • Cristine Allmer

  • Allison C. Rosenthal

  • Thomas M. Habermann

  • Andrew L. Feldman

  • Lisa M. Rimsza

  • Rebecca L. King

  • Melissa C. Larson

  • Bri J. Negaard

  • Aaron D. Norman

  • Nikhil Rajkumar

  • Stephen M. Ansell

  • Angela Dispenzieri

  • David L. Murray

  • Vincent Rajkumar

  • Shaji Kumar

  • Jithma P. Abeykoon

  • Grzegorz S. Nowakowski

  • Thomas E. Witzig

  • Anne J. Novak

  • Susan L. Slager

  • Celine M. Vachon

  • James R. Cerhan

  • April 19, 2025

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology-Oncology
    • Cancer Genetics
    • Genomic Medicine

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology-Oncology
    • Cancer Genetics
    • Molecular Pathology

  • #3

    National Cancer Institute (NCI)
    National Cancer Institute (NCI)

    Bethesda, MD

    Key Differentiators

    • Cancer Epidemiology
    • Genetics
    • Hematology-Oncology

  • #4

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology-Oncology
    • Cancer Genetics
    • Translational Research

  • #5

    University of Pennsylvania (Perelman School of Medicine)
    University of Pennsylvania (Perelman School of Medicine)

    Philadelphia, PA

    Key Differentiators

    • Hematology-Oncology
    • Cancer Genetics
    • Genomic Medicine

Original Source(s)

Risk of lymphoid malignancy associated with cancer predisposition genes

  • by Nicholas J. Boddicker, Raphael Mwangi, Dennis P. Robinson, Cristine Allmer, Allison C. Rosenthal, Thomas M. Habermann, Andrew L. Feldman, Lisa M. Rimsza, Rebecca L. King, Melissa C. Larson, Bri J. Negaard, Aaron D. Norman, Nikhil Rajkumar, Stephen M. Ansell, Angela Dispenzieri, David L. Murray, Vincent Rajkumar, Shaji Kumar, Jithma P. Abeykoon, Grzegorz S. Nowakowski, Thomas E. Witzig, Anne J. Novak, Susan L. Slager, Celine M. Vachon, James R. Cerhan

  • April 19, 2025

Related Content

Differentiation therapy in acute myeloid leukaemia: molecular basis, clinical progress, and future perspectives

Advancing CAR-T therapy in multiple myeloma: a critical appraisal of CARTITUDE-4 and the path toward earlier lines

Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report